Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-96

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 96 Last

Share
Profile

Follow
mumstheword

2,531 Posts.

272

15/11/19

13:10

Post #: 41446648
Share

Originally posted by ozemania ↑

This agreement seems to relate to a specific new initiative they are exploring with Sanofi. At this point the agreement is formalising the partnership between RAP and Sanofi on whatever may come of the initiative as it evolves over the next few months. There is an end date to the agreement, and fair to assume that by that point, they expect to know one way or another what will come out of it.

This doesnt imply RAP cant collaborate with other partners on other initiatives, it just protects both parties in the event that they can establish a marketable outcome out of whatever they are working on together at the moment.

Sanofi is one of the giants of the industry. Partnering with Sanofi is as good as partnering with anyone. A commercial outcome from this initiative will mean the ability to bring it to market rapidly (globally if they choose) with very little effort. Sanofi is well equipped with deep pockets, massive global footprint, plenty of infrastructure and plenty of resource and like its peers, a desire to stay ahead of the curve. Exclusivity around whatever they come up with will ensure that its worth Sanofi's effort today.

We will have to wait and see if it results in something commercial to get excited about, but at this stage its good to see yet another iron in the fire.

Expand

And... not forgetting anything that might morph out of our relationship with LM.
Personally, I think that 30 day escape clause is pure brilliance. Come one, come all!!! Apple, Google, Ping An good doc... etc etc

RAP Price at posting: 27.0¢ Sentiment: Buy Disclosure: Held
20 Upvote

0 Great analysis

Reply

Top Stories

HAS

Hastings progressing Yangibana to production with lower costs

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The iron ore comeback: Can it last?